Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Take a look at some of the latest COVID-19 developments:
Monoclonal antibody treatment authorized: The FDA on Saturday issued an emergency use authorization (EUA) for a combination monoclonal antibody treatment — casirivimab plus imdevimab — for patients with mild-to-moderate COVID-19 who are at high risk for developing severe disease (for example, adults aged 65 and older). This is the same treatment given to President Trump early in his illness. The intravenous antibody combination is authorized for patients aged 12 years and older who weigh at least 40 kg. It is not authorized for those who are hospitalized or require oxygen therapy for COVID-19. The EUA was issued based on findings from a randomized trial among some 800 outpatients with mild-to-moderate COVID-19. In that trial, patients who received casirivimab plus imdevimab were less likely to be hospitalized or visit the emergency department within 28 days than those who received placebo.
Baricitinib-remdesivir combo authorized: The FDA late last week issued an EUA for the combination of baricitinib (an oral janus kinase inhibitor) and remdesivir to treat hospitalized COVID-19 patients aged 2 years and older who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. In a randomized trial among some 1000 patients, those given remdesivir plus baricitinib — versus remdesivir plus placebo — had a shorter time to recovery and were less likely to die or need mechanical ventilation within 29 days of treatment.
CDC, asymptomatic transmission & masks: Over 50% of COVID-19 transmissions may result from presymptomatic or asymptomatic spread, the CDC says in an updated scientific briefing that endorses universal face masking. The agency notes: "The prevention benefit of masking is derived from the combination of source control and personal protection for the mask wearer. The relationship between source control and personal protection is likely complementary and possibly synergistic, so that individual benefit increases with increasing community mask use." The CDC also cited data showing that increasing universal masking by 15% could prevent lockdowns and decrease losses by up to $1 trillion. At the same time, the agency published an MMWR article showing that in Kansas, counties that required masks in public experienced a 6% decrease in COVID-19 incidence last summer, while counties without mask mandates saw a 100% increase.
Test sensitivity vs. frequency: The frequency of SARS-CoV-2 testing at the population level is more important than test sensitivity for controlling the pandemic, according to a modeling study in Science Advances. Researchers sought to determine the effects of screening at different frequencies using gold-standard PCR versus point-of-care nucleic acid LAMP and rapid antigen tests. In addition to finding that high test sensitivity only "marginally improved" screening, they found that test result delays led to "dramatically less effective control of viral spread." They conclude, "Screening should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."
Comment
LINK(S):
FDA news release on monoclonal antibody EUA (Free)
FDA news release on baricitinib-remdesivir combo EUA (Free)
CDC scientific brief on masks (Free)
MMWR article on masks in Kansas (Free)
Science Advances article on test sensitivity vs. frequency (Free)
NEJM Journal Watch COVID-19 page (Free)
NEJM COVID-19 page (Free)